Abraxane批准治疗晚期肺癌

(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung cancer among people who aren't candidates for surgery or radiation therapy, the agency said Friday.

2005年首次批准了Abraxane以治疗乳腺癌。

在新的1,038人的新临床研究中，对药物最常见的不良反应是贫血，丧失头发，恶心，疲劳，食欲不规，不规则，皮疹和肿胀。

Abraxane由Celgene Corp.生产，基于峰会，N.J.

---

---

版权所有©2012.健康天。版权所有。